|
|
Infliximab in dermatological treatment: beyond psoriasis.| Authors: | Dimitris Rigopoulos, Chrysovalantis Korfitis, Stamatis Gregoriou, Andreas D Katsambas | | Language: | Eng. | | Date: | 17-12-2007 | | Journal: | Expert opinion on biological therapy
(1744-7682)
| | Release: | Expert Opin Biol Ther. 2008 Jan;8(1):123-33 | |
|
|
Abstract:
|
Infliximab is a chimeric monoclonal antibody of the IgG1 class. Experience from its use has been accumulated in rheumatology and gastroenterology by the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and inflammatory bowel disease, respectively. Because of its TNF-alpha binding capacity it has been approved for the treatment of moderate-to-severe plaque psoriasis. Moreover, it has also been evaluated in other inflammatory dermatoses as well as systemic diseases involving the skin such as severe atopic dermatitis, pityriasis rubra pilaris, pyoderma gangrenosum and cutaneous sarcoidosis. The possible future uses of infliximab in dermatology are being reviewed herein.
| | Copyright: | Expert opinion on biological therapy
University of Athens, Department of Dermatology, 'A. Sygros' Hospital, 5 Ionos Dragoumi Street, Athens 16121, Greece. drigop@hol.gr | | Full text: |  EBSCO - HTML (needs subscription) | | Terms: | Antibodies, Monoclonal, Clinical Trials as Topic, Dermatologic Agents, Humans, Psoriasis, Skin Diseases, Tumor Necrosis Factor-alpha | | |
|
|
|
|  Add to my archive |
Articles from other specialties: Forensic and Legal Medicine, Gastrointestinal Surgery, Nursing, Vascular Surgery - Angiology, Anaesthesiology, Otorhinolaryngology, Rehabilitation, Radiology, Dermatology, Traumatology - Orthopaedics, Endocrinology, Oncology |
